Affecting roughly 5,000 people in the U.S., C3 glomerulopathy and immune-complex MPGN are two rare glomerulopathies ...

Janux Therapeutics' cash runway is about 12 months; dilution is likely, and upcoming data from both JANX007 and JANX008 are ...

Silevertinib delivers robust anti-tumor activity as demonstrated by an ORR of 60% and a CNS response rate of 86% in 43 1L NSCLC patients presenting with 35 different non-classical EGFR mutations; no ...

An aggressive breast cancer lacking common drug targets, triple-negative breast cancer may be countered by oridonin, a ...

Lung cancer remains the most frequently diagnosed malignancy and the leading cause of cancer tumour-related mortality ...

Surviving longer and remaining healthier in later life is influenced by many factors beyond classical blood lipids. A growing ...

FDA extends Ascendis' TransCon CNP review to Feb. 28, 2026, after new data submission related to post-marketing study ...

Seven courses were recommended for addition and one for deletion by the district’s Secondary Curriculum Review Committee.

Following its latest earnings and regulatory guidance, Sangamo Therapeutics has seen its fair value estimate hold steady at $3.25 per share, while its discount rate ticked up marginally from 7.28% to ...

Otsuka receives US FDA accelerated approval for Voyxact to reduce proteinuria in adults with IgAN: Princeton, New Jersey Thursday, November 27, 2025, 12:00 Hrs [IST] Otsuka Pharma ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 27, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; ...

Race Oncology has received the St Vincents Hospital Melbourne Human Research Ethics Committee (HREC) approval to begin a ...